Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin

Br J Clin Pharmacol. 1995 Jun;39(6):700-3. doi: 10.1111/j.1365-2125.1995.tb05732.x.


Twenty-six healthy males took part in this double-blind, randomised, placebo-controlled, two-period, cross-over study. Pantoprazole (40 mg) (test) or placebo (reference) were administered once daily, for 8 days, with a 3 week washout period. A single oral dose of 25 mg warfarin sodium was co-administered with pantoprazole or placebo on Day 2 of each treatment period. The 90% confidence intervals for the 'test/reference' mean ratios of the excess AUC(0.168 h) of prothrombin time and AUC(0.168 h) of factor VII, and of Cmax, AUC and t1/2 of both R- and S-warfarin fell within the equivalence range of 80% to 125%. These results suggest that pantoprazole does not alter the pharmacokinetics or pharmacodynamics of warfarin.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Benzimidazoles / pharmacology*
  • Blood Coagulation / drug effects
  • Cross-Over Studies
  • Double-Blind Method
  • Drug Interactions
  • Humans
  • Male
  • Omeprazole / analogs & derivatives
  • Pantoprazole
  • Proton Pump Inhibitors
  • Sulfoxides / pharmacology*
  • Warfarin / blood
  • Warfarin / pharmacokinetics
  • Warfarin / pharmacology*


  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Benzimidazoles
  • Proton Pump Inhibitors
  • Sulfoxides
  • Warfarin
  • Pantoprazole
  • Omeprazole